E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bipolar I disorder, manic or mixed episodes |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the efficacy of licarbazepine 750-2000 mg/d added to lithium or valproate in the treatment of manic episodes of bipolar I disorder by testing the following hypothesis: Licarbazepine added to lithium or valproate is superior to placebo combined with lithium or valproate in the reduction of the mean total score of the Young Mania Rating Scale (Y-MRS) from baseline to endpoint (Week 6). |
|
E.2.2 | Secondary objectives of the trial |
• To study the safety and tolerability of licarbazepine 750-2000 mg/d added to lithium or valproate in patients with manic episodes of bipolar I disorder by comparing licarbazepine added to lithium or valproate to placebo added to lithium or valproate with respect to the rates of adverse events and serious adverse events, as well as changes in laboratory values, ECGs and vital signs during the 6-week treatment. • To determine the efficacy of licarbazepine 750-2000 mg/d added to lithium or valproate in the treatment of manic episodes of bipolar I disorder by testing the following hypothesis: Licarbazepine added to lithium or valproate is superior to placebo added to lithium or valproate in the proportion of patients with a ≥50% reduction of the baseline Y-MRS at endpoint. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. males and females, 18 through 70 years of age; 2. diagnosis of bipolar disorder type I, manic or mixed episodes according to DSM-IV criteria (i.e., 296.0, 296.4 or 296.6), including patients with/without psychotic features or with/without a history of rapid cycling; 3. total score of at least 20 on the Young Mania Rating Scale (Y-MRS) at screening and at least 18 at baseline; 4. need of psychiatric treatment; 5. cooperation and willingness to complete all aspects of the study, including hospitalization; 6. written informed consent provided prior to participation in the study. |
|
E.4 | Principal exclusion criteria |
1. current DSM-IV Axis-I diagnosis other than bipolar I disorder; 2. history of schizophrenia or schizoaffective disorder; 3. concomitant use of psychoactive medication other than lorazepam, lithium or valproate, whereby the washout time between the last dose of prior medication and the beginning of the Pre-randomization Treatment Phase (Day -7) is dependent on the medication: • oral antipsychotics, mood stabilizers (carbamazepine, lamotrigine, etc.), antidepressants and sedatives (benzodiazepines, zolpidem, zopliclone): 5 half lives. The last dose of lorazepam must be at least 12 hours before screening and baseline assessments • depot antipsychotics, MAOIs: 4 weeks; 4. use of warfarin, tolbutamide, iodide salts, or zidovudine during the study; 5. drug dependence during the one month prior to screening. Drug dependence is defined by DSM-IV criteria; 6. positive urine drug screen at screening visit (or at repeat screening within 1 week of initial drug screen failure) for amphetamines, cocaine, hallucinogens, or opiates; 7. history of suicide attempt within the past one month prior to screening or immediate risk of harm to self or others at the time of screening, as judged by the Investigator; 8. mental retardation according to DSM-IV criteria; 9. female patients of childbearing potential who are not using effective contraception during the study, are breast feeding, or have a positive pregnancy test (β-hCG) at screening or baseline. Effective contraceptive measures are the following: • A hormonal oral, transdermal, or injectable contraceptive agent with a double-barrier method • An implantable contraceptive device for at least 3 months prior to screening with a double-barrier method • A triple barrier-method of contraception (condom, diaphragm and a spermicide); 10. serum sodium ≤130 mmol/L or history of multiple episodes of hyponatremia (defined as serum Na ≤125 mmol/L); 11. any sensory or motor deficits that may prevent the patient from completing any of the study assessments; 12. any non-psychiatric coexistent illness (e.g., diabetes mellitus, hypothyroidism) that has not been maintained in a stable condition for at least 3 months prior to baseline; 13. clinically significant abnormal conditions of the gastrointestinal system, liver, or kidneys, which could result in the possibility of altered absorption, excess accumulation, or impairment of metabolism or excretion of the double-blind or open-label study drug; 14. The Investigator should be guided by evidence such as the following: • recent major gastrointestinal tract surgery (e.g., gastrectomy, gastroenterostomy, bowel resection, etc.) • currently active peptic ulcer, ulcerative colitis, or regional ileitis; 15. history of serious dermatological reaction while being treated with an antiepileptic medication; 16. twice the upper normal limit at screening and upon repeated measurement for any one of the following laboratory parameters: SGOT, SGPT, LDH, alkaline phosphatase, or bilirubin; BUN values ≥30 mg/dL or creatinine clearance <30 mL/min; 17. any other clinically significant abnormal laboratory findings at screening which remain abnormal upon repeated measurement; • any of the following serological findings: • a positive hepatitis A antibody (IgM) • a positive hepatitis B surface antigen (HBsAg) • a positive hepatitis B core antibody (Anti-HBcAb), along with a negative hepatitis B surface antibody (Anti-HBsAb), in the setting of abnormal liver enzymes or recent clinical symptoms of hepatitis (within the last 2 months); 18. current diagnosis or recent past history of epilepsy, major head trauma, or progressive neurological disease (e.g., Parkinson’s disease, ALS); 19. known hypersensitivity to lithium or valproate or drugs chemically related to licarbazepine (e.g., oxcarbazepine, carbamezapine); 20. exposure during the 30 days preceding screening to any drug not registered for use in the country where the study is being conducted; 21. electroconvulsive therapy (ECT) within the 3 months preceding baseline; 22. any form of psychotherapy within the one month preceding screening; 23. hospitalization for mania due to a court order; 24. patients who are under legal supervision or guardianship; 25. a documented history of non-response to lithium or valproate, whereby non-response is defined by the treating physician who documented the history. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy: The primary efficacy variable is the change from baseline to endpoint (Week 6) in the total score of the Y-MRS score.
Safety: The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g. electrocardiogram, vital signs, and special tests) will be considered as appropriate. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 7 |